Market Overview
- Exascale Labs (XLAB)
- Current price: $2.99
- Trading volume (last 24 h): $25.1 million
- Shares outstanding: 91.2 million
- Market capitalization: $279.1 million
- 24‑hour change: ‑2.29 % (down from $3.06)
- 30‑day change: +6.79 % (up from $2.82)
- 200‑day simple moving average: $8.31
- 52‑week high: $11.17 (on 06/03/2026)
- 52‑week low: $0.78 (on 10/15/2026)
Related Stock Performance (Last 24 h)
| Ticker | Current Price | 24‑Hour Change | Market Cap (USD mn) | PE Ratio |
|---|---|---|---|---|
| CV | $6.68 | +0.15 % | 333.8 | – |
| LWAY | $22.42 | +1.17 % | 334.8 | 31.98 |
| NAUT | $2.55 | –3.04 % | 334.7 | – |
| BEAG | $10.58 | –0.75 % | 333.9 | 42.58 |
| IDR | $21.40 | +1.71 % | 333.0 | 28.18 |
All figures are rounded to two decimal places and reflect market conditions as of 11:39 AM Central Europe on Wednesday, 21 March 2026.
Summary
Exascale Labs experienced a modest decline of 2.29 % in the most recent 24‑hour trading period, while maintaining a strong overall trend of 6.79 % upward movement since the end of the previous month. The company’s valuation metrics—including its current market capitalization of $279.1 million and 200‑day simple moving average of $8.31—remain within the range observed over the past year. Comparable performance among peer companies shows a mix of small gains and losses, with Lifeway Foods and Idaho Strategic posting positive returns, and Nautilus Biotechnology and Bold Eagle Acquisition Corp recording declines.
